Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

VJOncology

- PMLiVE

Merck’s Keytruda beats BMS’ Yervoy in melanoma face-off

Both firms competing for a leading share in the highly competitive skin cancer drug market

- PMLiVE

Novo Nordisk sheds autoimmune portfolio to BMS

Continues the trend of pharma buying up unwanted assets from rival firms

- PMLiVE

Cancer charity partners with research council for innovation

CRUK teams up with multi-disciplinary groups to help develop new oncology products

- PMLiVE

EMA elects Dr Christa Wirthumer-Hoche new vice chair

Head of the Austrian regulator succeeds Prof DrWalter Schwerdtfeger

Seismic shifts: Hepatitis C and payers

How hep C is causing paradigm changes in payer behaviour

- PMLiVE

Dendreon wins IQWiG U-turn for its immunotherapy Provenge

New data for its troubled cancer drug convinces German HTA body of its added benefit

- PMLiVE

Lilly/Boehringer’s diabetes combination Glyxambi debuts in US

Companieslaunch first fixed-dose of empagliflozin and linagliptin

Eli Lilly HQ

Pfizer and Lilly restart tanezumab pain trials

FDAlifts clinical block on late-stage studies of the novel painkiller

- PMLiVE

Takeda spends $230m on oncology biotech deal

Buys into ImmunoGen’s antibody-drug conjugate technology

- PMLiVE

Merck KGaA supports Get Tested colorectal cancer campaign

Coincides with the first World Metastatic Colorectal Cancer Day

- PMLiVE

The Purple Agency appoints Andrew Jenkins and Terri Martin

Jenkinsjoins from FTI Strategic Communications and Martin comes from Porterhouse

- PMLiVE

The end of hepatitis C?

Next-gen hep C therapies may see the disease's global elimination - but treament access must be stepped up dramatically

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links